TY - JOUR
T1 - Thrombophilia Screening in Young Patients With Cryptogenic Ischemic Stroke
AU - Abels, Sofie
AU - Sihvo, Maximillian
AU - Tomppo, Liisa
AU - Kutal, Shakar
AU - Martinez-Majander, Nicolas
AU - Tulkki, Lauri
AU - Sarkanen, Tomi
AU - Jakala, Pekka
AU - Redfors, Petra
AU - Huhtakangas, Juha
AU - Ylikotila, Pauli
AU - von Sarnowski, Bettina
AU - Yesilot, Nilufer
AU - Waje-Andreassen, Ulrike
AU - Fonseca, Ana Catarina
AU - Martinez Sanchez, Patricia
AU - Korv, Janika
AU - Ferdinand, Phillip
AU - Ryliskiene, Kristina
AU - Pezzini, Alessandro
AU - Licenik, Radim
AU - Zedde, Marialuisa
AU - Lehto, Mika
AU - Sinisalo, Juha
AU - Gerdts, Eva
AU - Ten Cate, Hugo
AU - Helin, Tuukka A.
AU - Joutsi-Korhonen, Lotta
AU - Szanto, Timea
AU - de Leeuw, Frank-Erik
AU - Putaala, Jukka
PY - 2026/5/1
Y1 - 2026/5/1
N2 - BACKGROUND: – The incidence of cryptogenic ischemic stroke (CIS) in young adults is increasing, particularly among those without traditional vascular risk factors. Thrombophilia may contribute to CIS pathogenesis, yet guidelines differ on the relevance of screening. We investigated the sex-specific prevalence of routinely applied thrombophilia screening in young-onset CIS and its association with clinical characteristics and standard laboratory results. METHODS: – We included young patients with CIS aged 18 to 49 years from the SECRETO study (Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Triggers, Causes, and Outcome). Routinely used thrombophilia panels obtained at admission and repeated testing within 1 year of stroke were analyzed. Ten thrombophilia markers were assessed and categorized according to the grade of deviation into lowest, low, and high thrombosis risks. Factors associated with any deviation in thrombophilia markers were investigated with multivariable logistic regression. RESULTS: – Of 598 initially enrolled patients with CIS, 556 undergoing baseline thrombophilia testing were analyzed (median age, 41.0 [interquartile range, 34.1–45.8] years; male:female ratio 1.2:1). Of these, 120 (21.6%) and 36 (6.5%) were retested by 3 and 12 months, respectively. At baseline, any thrombophilia abnormality was observed in 206 patients (37.1%; men, 38.2%; women, 35.7%). High-risk thrombophilia was identified in 29 patients (5.2%) at baseline, in 13 retested patients (11.1%) at 3 months, and in 5 retested patients (13.9%) at 12 months. Overall, 45 patients (8.1%) had persistent thrombophilia abnormalities (men, 7.9%; women, 8.3%). Physical inactivity, a history of venous thromboembolism, low HDL (high-density lipoprotein)-cholesterol, and low hemoglobin were associated with any deviation in the thrombophilia markers. Anticoagulation was initiated in 50.0% of patients with abnormal baseline thrombophilia versus 35.7% without (P=0.042) and in 26.9% versus 6.2% with and without persistent abnormalities (P<0.001). CONCLUSIONS: – Over a third of young adults with CIS had thrombophilia deviations at admission although high-risk thrombophilia results remained rare. Screening may be considered in young patients with CIS with a history of venous thromboembolism, physical inactivity, and low hemoglobin or HDL-cholesterol.
AB - BACKGROUND: – The incidence of cryptogenic ischemic stroke (CIS) in young adults is increasing, particularly among those without traditional vascular risk factors. Thrombophilia may contribute to CIS pathogenesis, yet guidelines differ on the relevance of screening. We investigated the sex-specific prevalence of routinely applied thrombophilia screening in young-onset CIS and its association with clinical characteristics and standard laboratory results. METHODS: – We included young patients with CIS aged 18 to 49 years from the SECRETO study (Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Triggers, Causes, and Outcome). Routinely used thrombophilia panels obtained at admission and repeated testing within 1 year of stroke were analyzed. Ten thrombophilia markers were assessed and categorized according to the grade of deviation into lowest, low, and high thrombosis risks. Factors associated with any deviation in thrombophilia markers were investigated with multivariable logistic regression. RESULTS: – Of 598 initially enrolled patients with CIS, 556 undergoing baseline thrombophilia testing were analyzed (median age, 41.0 [interquartile range, 34.1–45.8] years; male:female ratio 1.2:1). Of these, 120 (21.6%) and 36 (6.5%) were retested by 3 and 12 months, respectively. At baseline, any thrombophilia abnormality was observed in 206 patients (37.1%; men, 38.2%; women, 35.7%). High-risk thrombophilia was identified in 29 patients (5.2%) at baseline, in 13 retested patients (11.1%) at 3 months, and in 5 retested patients (13.9%) at 12 months. Overall, 45 patients (8.1%) had persistent thrombophilia abnormalities (men, 7.9%; women, 8.3%). Physical inactivity, a history of venous thromboembolism, low HDL (high-density lipoprotein)-cholesterol, and low hemoglobin were associated with any deviation in the thrombophilia markers. Anticoagulation was initiated in 50.0% of patients with abnormal baseline thrombophilia versus 35.7% without (P=0.042) and in 26.9% versus 6.2% with and without persistent abnormalities (P<0.001). CONCLUSIONS: – Over a third of young adults with CIS had thrombophilia deviations at admission although high-risk thrombophilia results remained rare. Screening may be considered in young patients with CIS with a history of venous thromboembolism, physical inactivity, and low hemoglobin or HDL-cholesterol.
KW - adult
KW - case-control studies
KW - ischemic stroke
KW - risk factors
KW - stroke
KW - thrombophilia
KW - RISK-FACTORS
KW - ADULTS
KW - MUTATIONS
KW - AGE
U2 - 10.1161/STROKEAHA.125.053251
DO - 10.1161/STROKEAHA.125.053251
M3 - Article
SN - 0039-2499
VL - 57
SP - 1242
EP - 1255
JO - Stroke
JF - Stroke
IS - 5
ER -